Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00147485 · ClinicalTrials.gov registry record · Phase 1
A Phase 1 Study Of An Intravenously Administered Cyclin-Dependent Kinase Inhibitor In Patients With Advanced Cancer
A Phase 1 study, sponsored by Pfizer.
- Terminated
- Registry status
- Phase 1
- Development phase
- 37
- Enrollment target
NCT00147485 is a Phase 1 study that was terminated before completion, run by Pfizer. The registered enrollment target is 37 participants.
The verdict
NCT00147485, a Phase 1 study, was terminated before completion, sponsored by Pfizer.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 37 participants
- Enrollment target
Study Summary
AG-024322 may work in cancer by stopping cancer cells from multiplying. AG-024322 is and intravenous drug from a new class of drugs call cyclin-dependent kinase (CDK inhibitors). This research study is the first time that AG-024322 will be given to people.
Interventions
- DRUG AG-024322
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 37 participants |
| Start Date | 2004-12 |
| Est. Completion | 2007-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00147485
The ClinicalTrials.gov registry entry for NCT00147485 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 37 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which AG-024322 is the first listed.
NCT00147485 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00147485 about?
NCT00147485 is a clinical study titled "A Phase 1 Study Of An Intravenously Administered Cyclin-Dependent Kinase Inhibitor In Patients With Advanced Cancer". AG-024322 may work in cancer by stopping cancer cells from multiplying. AG-024322 is and intravenous drug from a new class of drugs call cyclin-dependent kinase (CDK inhibitors). This research study is the first time that AG-024322 will be given to people.
What is the current status of trial NCT00147485?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 37 participants. The study started on 2004-12. Estimated completion is 2007-08.
What interventions are being tested in trial NCT00147485?
The interventions under investigation include: AG-024322 (DRUG).
Who is sponsoring clinical trial NCT00147485?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.